Hsbc Holdings PLC Makes New $1.06 Million Investment in Celcuity, Inc. $CELC

Hsbc Holdings PLC acquired a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 10,636 shares of the company’s stock, valued at approximately $1,058,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE grew its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the period. Meeder Asset Management Inc. bought a new position in Celcuity during the fourth quarter valued at about $42,000. Finally, Ogorek Anthony Joseph NY ADV raised its holdings in Celcuity by 19.7% in the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by insiders.

Celcuity Price Performance

Celcuity stock opened at $103.79 on Tuesday. The business has a 50 day simple moving average of $111.44 and a 200 day simple moving average of $111.07. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The company has a market capitalization of $5.06 billion, a PE ratio of -26.61 and a beta of 0.16. Celcuity, Inc. has a one year low of $13.36 and a one year high of $151.02.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. On average, sell-side analysts forecast that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on CELC. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Craig Hallum reduced their target price on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research note on Monday, May 4th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.09.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.